Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Otsuka’s Pharma Sales Up 3.3% in 2020 Driven by 4 Global Brands
February 15, 2021
- Kringle, Keio Univ. Sign Research Pact on HGF Therapy for Spinal Cord Injury
February 15, 2021
- JCR’s Hurler Syndrome Drug Gets Orphan Status in US
February 15, 2021
- Sumitomo Dainippon Cuts Operating Profit Outlook on Napabucasin Flop
February 15, 2021
- JCR Pharma’s JR-141 Gets FDA’s Fast-Track Status
February 12, 2021
- Takeda Files Its 1st Cell Therapy, Darvadstrocel, in Japan
February 12, 2021
- Japan Trial Now Underway for Gene Therapy Luxturna; Eyes Riveted on Its Price Tag
February 12, 2021
- Kobayashi Kako Chief to Resign over Drug Mix-Up, Lousy Manufacturing and Cover-Ups
February 10, 2021
- Chugai to Discuss Filing of Actemra for COVID-19 with Japanese Regulators
February 10, 2021
- Keytruda Top-Seller for 6 Months on End: Encise
February 10, 2021
- Napabucasin Fails in PIII for Colorectal Cancer: Sumitomo Dainippon
February 10, 2021
- Japan Ethical Drug Sales Down 3.9% in December: Crecon
February 9, 2021
- Rakuten Medical’s Photoimmunotherapy Now Available in Japan
February 9, 2021
- 7 Japan Drug Majors See 2.7% Revenue Fall in FY2020, COVID-19 Forces Cuts on Guidance: Jiho Tally
February 8, 2021
- 1st Oral GLP Agent Hits Japan Shelves
February 8, 2021
- Chugai COO Okuda to Become CEO, Kosaka to Stay as Chairman
February 8, 2021
- Chugai Targets 1 Global Product Launch Each Year: New Growth Strategy
February 8, 2021
- Kyowa Kirin Aims for CAGR of 10% towards 500 Billion Yen Target by 2025: New Biz Plan
February 8, 2021
- Health Minister Hails Domestic Production Plan for AstraZeneca Vaccine
February 8, 2021
- AstraZeneca Files COVID-19 Vaccine in Japan
February 5, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…